US appeals court clears Abbott in Norvir antitrust case
This article was originally published in Scrip
Executive Summary
Abbott Laboratories has won a federal appeals court ruling dismissing claims that it violated antitrust laws when it increased the price of Norvir (ritonavir), often used to "boost" the effect of other HIV protease inhibitors, by 400%. A three-judge panel for the US Court Appeals for the Ninth Circuit, San Francisco, made the ruling on July 7th.